Entinostat Plus Pembrolizumab Shows Promise in Previously Treated Melanoma
Cancer Network spoke with Ryan J. Sullivan, MD, about the efficacy and safety of entinostat plus pembrolizumab in patients previously treated with immunotherapy.
Cancer Network spoke with Ryan J. Sullivan, MD, about the efficacy and safety of entinostat plus pembrolizumab in patients previously treated with immunotherapy.
Newsletter
Stay up to date on recent advances in the multidisciplinary approach to cancer.
Recent Videos
![A third of patients had a response [to lifileucel], and of the patients who have a response, half of them were alive at the 4-year follow-up.](/_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fcancernetwork%2F6b7c9a3270c71a70749ba86000cfc78a29d74309-2988x1702.png%3Ffit%3Dcrop%26auto%3Dformat&w=3840&q=30 "A third of patients had a response [to lifileucel], and of the patients who have a response, half of them were alive at the 4-year follow-up.")
Related Content
